Advanced Biomed Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsAdvanced Biomed Inc. is an early-stage cancer diagnostics company developing microfluidic-based circulating tumor cell detection and 3D cell culture products.
What they do
Advanced Biomed Inc., a Nevada holding company, operates through subsidiaries in Taiwan, Hong Kong, and Shanghai. The company designs and develops microfluidic biochips and medical testing equipment for the detection, isolation, and analysis of circulating tumor cells (CTCs) and related tumor markers. Its product portfolio includes devices (A+Pre, AC-1000, A+CellScan, A+SCDrop), matching microfluidic biochips, immunostaining kits, and the A+PerfusC 3D cell culture system. The company has not yet commenced manufacturing or sales of any products.
Revenue drivers
- CTC detection devices and chips — Devices and chips (A+Pre, AC-1000, A+CellScan, A+SCDrop, and chips) are designed for early cancer screening and CTC detection; no sales yet, so no revenue.
- Immunostaining kits — Four kits (A+CTCE, A+CTCM, A+EMT, A+CM) for identifying different CTC types; R&D completed and registration applications submitted in China, but not commercialized.
- Lung cancer screening kit — A+LCGuard, a Class III medical device for lung cancer early screening, is in development; clinical research planned to begin November 2025, no revenue.
- A+PerfusC system — An all-in-one perfusion-based 3D cell culture incubator supporting up to 12 days of culture; latest development, pre-commercialization.
Recent performance
For fiscal 2024, net loss was $2.8 million and diluted EPS was -$0.14; for fiscal 2025, net loss widened to $3.3 million, with diluted EPS of -$0.16. Operating cash flow was -$2.1 million in 2024 and -$5.8 million in 2025. As of March 31, 2026, the company reported total assets of $10.6 million, total liabilities of $1.4 million, shareholder equity of $9.2 million, and cash & equivalents of $2.6 million. The company has no revenue, as it has not started manufacturing or sales.
Strategy
The company plans to first commercialize in China through its Hong Kong and Shanghai subsidiaries, focusing on local market operations, production, and product registration. It intends to conduct clinical trials for A+LCGuard, using clinical research to inform future trial design. Management also states plans to establish operation centers in North America and Europe in the future. The company is investing in R&D for its microfluidic platform and product pipeline.
Risks
- No revenue and early stage — The company has not started manufacturing or sales, making profitability and future performance highly uncertain.
- Regulatory approvals — Products require approvals from regulators like NMPA; delays or failures could prevent commercialization.
- Clinical trial uncertainty — A+LCGuard, a Class III device, requires clinical trials; results may not support progression, requiring product optimization or adjustments.
- Competition and market adoption — The precision oncology detection market is early stage and rapidly evolving; the company may fail to gain acceptance by hospitals and physicians.
Outlook
Management plans to begin clinical research for A+LCGuard in November 2025, with results expected to guide future large-scale trials. They acknowledge that clinical research outcomes may differ from expectations, potentially requiring product optimization. The company is also progressing registration applications for immunostaining kits in China. Forward-looking statements indicate focus on regulatory milestones and initial commercialization, but no timeline for revenue generation is provided.